Google Play mobile download button
Apple IOS mobile download button
Google Play mobile download button
Apple IOS mobile download button
HomeBusinessMirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug

Balanced News: Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug

Our 'quick read' news summary

Shares of Mirati Therapeutics Inc. MRTX, +0.10% jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a treatment for colorectal cancer. The drug is already approved to treat certain kinds of non-small cell lung cancer. Mirati’s stock has tumbled 71.8% so far this year, while the broader S&P 500 SPX, +1.49% is down 18.6%.

Read different perspectives from these news sources

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

More top reads from Balanced News Summary

Do you agree with this post's rating?
0
(0)
- Advertisment -
- Advertisment -